• Home
  • Congress & Events
  • 2024 ASCO Annual Meeting
  • Circulating KIM-1 biomarker analysis in IMmotion010, a randomized Phase 3 study of adjuvant atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

2024 ASCO Annual Meeting

May 31 - Jun 04, 2024 | Chicago USA/Virtual (Hybrid)

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Circulating KIM-1 biomarker analysis in IMmotion010, a randomized Phase 3 study of adjuvant atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection

Authors Laurence Albiges, Axel Bex, Cristina Suarez, Robert Uzzo, Xiaobin Tang, Zoe June Assaf, Sarita Dubey, Erik Goluboff, Corey Carter, Romain Banchereau, Mahrukh Huseni, Sumanta Pal, Brian Rini

Published date03 June, 2024

This oral presentation, using data from patients with RCC treated with adjuvant atezolizumab or placebo in the IMmotion010 trial, reports on a retrospective, exploratory analysis of circulating protein biomarkers to identify high-risk patients with minimal residual disease who may show differential benefit to atezolizumab treatment after resection.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

Not a healthcare professional? Browse:

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.